The table below shows Fulcrum Therapeutics, Inc.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
Line item
Q1 2026
Q1 2025
Q1 2024
Q1 2023
Q1 2022
Q1 2021
Operating cash flow
-$18.75M
-$15.26M
-$25.28M
-$24.12M
-$22.11M
-$16.23M
Capital expenditure
$8.00K
$0.00
$28.00K
$171.00K
$246.00K
$262.00K
Investing cash flow
-$128.21M
-$777.00K
$38.13M
-$93.94M
$19.66M
$12.41M
Dividends paid
-
-
-
-
FULC operating cash flow (10-K history)
Fulcrum Therapeutics, Inc. reported operating cash flow of -$60.06M for fiscal year 2025. That is down 2608.1% from -$2.22M in fiscal 2024. Over the 8 fiscal years shown, operating cash flow declined from -$22.56M (FY 2018) to -$60.06M. Figures come from the company's audited annual reports as filed with the SEC.